In the past week several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore, Synact Pharma announced a new CEO, while Genmab completed its share buy-back program.
10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date.
Company news the past week
Ascendis Pharma
Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism (LINK)
Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023 (LINK)
Oppenheimer Downgrades Ascendis Pharma to Market Perform
Analyseupdate in Swedish- Minskad risk efter positiva fas 1-studier – Mangold Insight Analys (LINK)
Cessatech
No news the past week
No news the past week
Notice of Annual General Meeting 2023 (LINK)
Evaxion Biotech
BioStock: Evaxion to sharpen focus and launch new platform (LINK)
Lake Street Capital Lowers Evaxion Biotech Price Target to $7.00
Expres2ion
No news the past week
Fluoguide
No news the past week
Genmab
Completion of share buy-back program (LINK)
1. Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (LINK)
2. Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (LINK)
Gubra
Completion of the offering and registration of capital increase in Gubra A/S (LINK)
Initiator Pharma
Initiator Pharma completes dosing in Phase 2a trial with IP2018 (LINK)
IO Biotech
No news past the week
Pila Pharma
CEO Dorte X. Gram announces further increase of its holding in Pila Pharma AB
Saniona
BioStock: Saniona´s obesity drug one step closer to approval (LINK)
BioStock: Saniona sees potential for value-creating milestones (LINK)
Scandion Oncology
No news past week
SynAct Pharma
SynAct Pharma appoints Torbjørn Bjerke as new CEO (LINK)
ViroGates
ViroGates announces preliminary results for Q1, 2023: Quarterly revenue affected by a slower-than-expected conversion of COVID-19 hospitals into use in triage in the emergency department (LINK)
Zealand Pharma
Zealand Pharma A/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq Copenhagen (LINK)
Zealand Pharma completes registration of capital increase (LINK)
Y-mAbs Therapeutics
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA (LINK)
2cureX
2CUREX STRENGTHENS ITS INDITREAT® AUTOMATION PROJECT WITH A PRESTIGIOUS GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH (LINK)
SHARE PRICE DEVELOPMENTS
Pila Pharma AB was the best performing Danish biotech company last week with a 27% increase after the CEO bought shares. At the opposite end of the spectrum was Ascendis Pharma A/S fell 32% after releasing dose results from the ongoing phase 1/2 trial of TransCon as well as a regulatory review. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Zealand Pharma A/S and Fluoguide AB have performed well. Saniona has made a strong comeback after several years of downturns. This follows a possible approval for the company’s weight loss lead-candidate in Mexcio, which could generate royalties for Saniona.
Read more about Fluoguide: The unique cancer treatment of the future – Today’s investment
